Agilent Technologies and Chungnam National University have agreed to develop new applications, methods, technologies and software tools in the field of glycomics ? the study of complex sugars.
Agilent Technologies and Chungnam National University have agreed to develop new applications, methods, technologies and software tools in the field of glycomics — the study of complex sugars. As a result of the agreement, the university aims to identify and develop biomarkers for diseases such as cancer, leading to the development of therapeutic antibody products. It is Agilent’s first partnership of this kind with a university in Asia.
“Chungnam National University, with our motto, ‘Creativity, development and service to the community’ has been offering the best possible environment for excellence in research and education for over 50 years,” said professor Kwang Hwa Chung, dean, Chungnam National University. “We are proud to announce this collaboration with Agilent that will see our university using the latest analytical and scientific technologies for research in glycomics.”
The research will be jointly led by Professor Hyun Joo An, department of analytical science and technology at Chungnam National University’s Graduate School of Analytical Science and Technology (GRAST) and head of the new Asia Glycomics Education Centre and by Rudolf Grimm, Agilent’s director of science and technology and manager of collaborations in the Asia Pacific region.
For further information, visit ref="http://www.agilent.com">www.agilent.com
Detangling the Complex Web of GC × GC Method Development to Support New Users
November 1st 2024In this article, the authors describe a simple workflow to develop a GC×GC method for a specific sample upon initial use, with the aim of decreasing the time to accomplish functional workflows for new users.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Green Chemistry: What is it (and What Is It Not)? And How Does It Apply to Gas Chromatography?
October 31st 2024Everyone is talking about sustainability, and organizations are creating sustainability programs. But what does green chemistry really mean, and how does it apply to gas chromatography?
AOAC International Awarded NIST Grant for Developing Drug Testing Standards
October 31st 2024The grant will be part of a new collaborative scientific initiative to address the need for standards that define the desired performance of lateral flow immunoassay test strips to detect illicit drugs in tablets and powders.